SCYX
4.84
+0.14 (+2.98%)
USD · NASDAQ
52-week range
3.53
9.20
Trading at 23% of the 52-week range
Market Cap
48.16M
P/E Ratio
0.00
Forward P/E
1.85
Book Value
6.73
Div. Yield
N/A
% Institutions
61.95%
% Insiders
2.00%

1 Year

-48.7%

3 Year

-82.8%

10 Year

-98.1%
Description

SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

Company Information

Company Name
Scynexis Inc
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Exchange
NASDAQ
ISIN: US8112923094
CIK: 0001178253
CUSIP: 811292101
Currency: USD
Full Time Employees: 18
Phone: 201 884 5485
Fiscal Year End: December
IPO Date: May 02, 2014
Description:

SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

Address:

1 Evertrust Plaza, Jersey City, NJ, United States, 07302-6548

People

Directors & Officers

Name Title Year Born
Dr. David Gonzalez Angulo M.D. CEO, President & Director 1965
Mr. Ivor Macleod CPA, M.B.A. Chief Financial Officer 1961
Mr. Scott Sukenick J.D. Chief Legal Officer & Corporate Secretary 1978
Ms. Daniella Gigante Vice President of Human Resources & Information Technology NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Sep 12, 2024 Gonzalez David Angulo N/A Purchase 20.00K $1.37 $27.40K

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Heights Capital Management Inc 2.09M Mar 31, 2026 2.62% $0.53 0.00%
Vanguard Capital Management, LLC 1.56M Mar 31, 2026 1.97% $0.00 0.00%
Great Point Partners LLC 944.29K Jun 30, 2026 9.49% $0.73 0.00%
Squadron Capital Management LLC 756.88K Jun 30, 2026 7.61% $0.96 -20.42%
Acadian Asset Management LLC 731.95K Mar 31, 2026 0.92% $0.00 0.00%
Propel Bio Management LLC 543.48K Jun 30, 2026 5.46% $1.16 0.00%
Adage Capital Partners Gp LLC 543.48K Jun 30, 2026 5.46% $0.00 0.00%
Geode Capital Management, LLC 486.37K Mar 31, 2026 0.61% $0.00 8.27%
BlackRock Inc 332.19K Mar 31, 2026 0.42% $0.00 -0.73%
Avidity Partners Management LP 260.21K Jun 30, 2026 2.62% $0.17 -50.00%
Kingdon Capital Management LLC 247.81K Jun 30, 2026 2.49% $0.10 0.00%
Vanguard Fiduciary Trust Co 225.74K Mar 31, 2026 0.28% $0.00 0.00%
Renaissance Technologies Corp 224.64K Mar 31, 2026 0.28% $0.00 27.64%
Yakira Capital Management, Inc. 188.60K Mar 31, 2026 0.24% $0.05 -0.63%
Millennium Management LLC 180.79K Jun 30, 2026 1.82% $0.00 132.47%
Dafna Capital Management LLC 135.87K Jun 30, 2026 1.37% $0.11 0.00%
Empery Asset Management, LP 126.45K Jun 30, 2026 1.27% $0.60 -45.25%
Bridgeway Capital Management, LLC 124.44K Mar 31, 2026 0.16% $0.00 -24.09%
Empowered Funds, LLC 123.70K Mar 31, 2026 0.16% $0.00 0.00%
State Street Corp 120.73K Mar 31, 2026 0.15% $0.00 0.00%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard MStar Total Stk Mkt Idx Invest 291.29K 2.93% ▲ 79.10% Jul 31, 2026
2 Vanguard Institutional Extnd Mkt Idx Tr 128.20K 1.29% ▲ 0.00% Jul 31, 2026
3 Extended Equity Market Fund B 80.95K 0.10% ▲ 0.00% Dec 31, 2025
4 Extended Equity Market Fund E 80.95K 0.10% ▲ 0.00% Dec 31, 2025
5 Fidelity Extended Market Index 52.12K 0.52% ▼ 0.19% Jul 31, 2026
6 NT Ext Eq Mkt Idx Fd DC Lending Tier 5 20.04K 0.03% ▼ 30.70% Mar 31, 2026
7 Fidelity Series Total Market Index 15.76K 0.16% ▲ 48.37% Jul 31, 2026
8 EA Bridgeway Omni Small-Cap Value ETF 15.46K 0.16% ▲ 0.00% Aug 31, 2026
9 NT Ext Equity Mkt Index Fund - Lending 12.44K 0.13% ▲ 96.03% Jun 30, 2026
10 Northern Trust Extended Eq Market Idx 12.44K 0.13% ▲ 96.03% Jun 30, 2026

Financial Highlights

Market Cap: $48.16M
EBITDA: $-36.54M
PEG Ratio: $0.00
Book Value: $6.73
Earnings/Share: $-0.91
Profit Margin: -53.26%
Operating Margin: -3,308.51%
ROA (TTM): -20.82%
ROE (TTM): -18.38%
Revenue (TTM): $19.22M
Revenue/Share (TTM): $2.50
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): -82.80%

Valuation Metrics

Enterprise Value: $-3.98M
Trailing P/E: 0.00
Forward P/E: 1.85

Shares Statistics

Shares Outstanding: 9.95M
Shares Float: 7.36M
% Insiders: 2.00%
% Institutions: 61.95%
Short % Float: 4.65%

Stock Price History

1 Year Price History

3 Years Price History

10 Years Price History

Financial Charts

Revenue, Net Income & Operating Cash Flow (Yearly)

Revenue, Net Income & Operating Cash Flow (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$20.60M
Gross Profit
subtotal
$20.60M
SG&A
adjust
$-14.40M
R&D
adjust
$-22.28M
Operating Income
subtotal
$-16.07M
Other / Non-Operating Items
adjust
$7.47M
Net Income
subtotal
$-8.61M

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about SCYX.US!